Cochrane · systematic review · CD015588
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes
Natale, P, Tunnicliffe, DJ, Toyama, T, et al. · Cochrane Database of Systematic Reviews · 2024 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 42.9%High 4 · 57.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors versus placebo for people with diabetes and chronic kidney disease
Population: people with CKD and diabetes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause death median Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors vs placebo | RR 0.86 [0.81, 0.92] | 20 studies · 44397 participants | High |
3P‐MACE median Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors vs placebo | RR 0.89 [0.81, 0.98] | 7 studies · 38320 participants | Moderate Downgraded: inconsistency |
4P‐MACE median Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors vs placebo | RR 0.82 [0.7, 0.96] | 4 studies · 23539 participants | Moderate Downgraded: inconsistency |
Kidney composite outcome median Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors vs placebo | RR 0.68 [0.59, 0.78] | 7 studies · 36380 participants | High |
Kidney failure median Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors vs placebo | RR 0.7 [0.62, 0.79] | 6 studies · 11232 participants | High |
Hypoglycaemia requiring third‐party assistance median Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors vs placebo | RR 0.75 [0.65, 0.88] | 14 studies · 26478 participants | High |
Diabetic ketoacidosis median Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors vs placebo | RR 2.05 [1.34, 3.14] | 13 studies · 38710 participants | Moderate Downgraded: inconsistency |